EUCTR2010-020337-99-SK进行中（未招募）1 期
A Randomized, Double-Blind, Double-Dummy, Parallel-Group Study To Evaluate The Efficacy And Safety Of Ocrelizumab In Comparison To Interferon Beta-1a (Rebif®) In Patients With Relapsing Multiple Sclerosis - OPERA I
F.Hoffmann-La Roche0 个研究点目标入组 821 人开始时间: 2010年10月14日最近更新:
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 821
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Male and female patients between ages 18-55 with a diagnosis of relapsing multiple sclerosis
- •At least 2 documented clinical attacks within the last 2 years prior to screening or one clinical attack in the year prior to screening (but not within 30 days prior to screening)
- •Patients with EDSS score of 0-5.5
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 800
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range 0
排除标准
- •Patients with other chronic disease of the immune system, malignancies or other diseases or conditions that could preclude patient from participating in the study
- •Contraindications to or intolerance of oral or i.v. corticosteroids
- •Contraindication to or intolerance of interferon beta-1a (Rebif)
- •Pregnant or nursing women
研究者
相似试验
进行中（未招募）
1 期
A Study of Ocrelizumab in Comparison With Interferon Beta-1a in Patients With Relapsing Multiple SclerosisRelapsing Multiple SclerosisMedDRA version: 21.1Level: PTClassification code 10063399Term: Relapsing-remitting multiple sclerosisSystem Organ Class: 10029205 - Nervous system disordersEUCTR2010-020337-99-ATF.Hoffmann-La Roche821
已完成
3 期
A Randomized, Double-Blind, Double-Dummy, Parallel-Group Study To Evaluate The Efficacy And Safety Of Ocrelizumab In Comparison To Interferon Beta-1a (Rebif®) In Patients With Relapsing Multiple SclerosisAutoimmune disorder of the central nervous system10007951MSNL-OMON43603Hoffmann-La Roche1
进行中（未招募）
1 期
A Study of Ocrelizumab in Comparison With Interferon Beta-1a in Patients With Relapsing Multiple SclerosisRelapsing Multiple SclerosisMedDRA version: 21.1Level: PTClassification code 10063399Term: Relapsing-remitting multiple sclerosisSystem Organ Class: 10029205 - Nervous system disordersEUCTR2010-020337-99-BGF.Hoffmann-La Roche821
进行中（未招募）
不适用
A Study of Ocrelizumab in Comparison With Interferon Beta-1a in Patients With Relapsing Multiple SclerosisRelapsing Multiple SclerosisMedDRA version: 14.0Level: PTClassification code 10063399Term: Relapsing-remitting multiple sclerosisSystem Organ Class: 10029205 - Nervous system disordersEUCTR2010-020337-99-ESF.Hoffmann-La Roche800
进行中（未招募）
不适用
A Randomized, Double-Blind, Double-Dummy, Parallel Group, Phase 3 Efficacy and Safety Study of CGT-2168 Compared with Clopidogrel to Reduce Upper Gastrointestinal Events including Bleeding and Symptomatic Ulcer Disease - COGENT-1, Clopidogrel and the Optimization of Gastrointestinal EventsEUCTR2007-005891-15-ITCOGENTUS PHARMACEUTICALS INTERNATIONAL LIMITED3,200